An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.
Sponsor: Kyowa Kirin Co., Ltd.
Terminated
Additional long-term safety data no longer needed
Other terminated trials from Kyowa Kirin Co., Ltd.
- Apathy · Dec 2023
- Diabetic Kidney Disease · Phase PHASE3 · Jul 2023
- Follicular Lymphoma (FL) · Phase PHASE3 · Mar 2023
- Urothelial Carcinoma · Phase PHASE1 · Nov 2022
- Healthy Volunteers · Phase PHASE1 · Aug 2022
More terminations from Kyowa Kirin Co., Ltd.
A PHASE3 clinical study on Parkinson's Disease, this trial is terminated or withdrawn. The trial is conducted by Kyowa Kirin Co., Ltd. and has accumulated 9 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jun 2024 [monthly]
Terminated PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Kirin Co., Ltd.
- Kyowa Kirin, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .